natgillin/translations-raw huggingface dataset:
CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to claim 1 or 2. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1 ili 2.
The device according to claim 1 wherein the base of the upright element and the baseplate are bonded together in the mutual fastening zone. 
Sustav prema zahtjevu 1, naznačen time da su baza (6) uspravnog elementa (5) i osnovna ploča (3) međusobno spojene u zoni međusobnog učvršćenja (7).
A process as in Claim 2, wherein the compound of formula (XI-S) is reacted with the compound of formula (VI-S) in the presence of a base; wherein the base is sodium hydroxide; and wherein the sodium hydroxide is present in an amount in the range of frm 1.05 to 1.2 molar equivalents. 
Postupak prema zahtjevu 2, naznačen time da spoj s formulom (XI-S) reagira sa spojem s formulom (VI-S) u prisutnosti baze; pri čemu baza je natrijev hidroksid; i pri čemu je natrijev hidroksid prisutan u količini u rasponu od 1.05 do 1.2 molarnih ekvivalenata.
with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms, 
i R2 koji mogu biti međusobno isti ili različiti, mogu biti vodik, alkil-skupina koja ima od 1 do 5 atoma ugljika ili alkoksi-skupina koja ima od 1 do 3 atoma ugljika,
at a pressure higher than the critical pressure of CO2. 
tlak viši od kritičnog tlaka CO2;
The reduction according to method 4 is performed by standard literature methods i.e. 
Redukcija u skladu s metodom 4 vrši se standardnim metodama opisanim u literaturi npr.
The method of claim 40 wherein the application is to a moving agricultural crop. 
Postupak prema zahtjevu 40, naznačen time što se nanošenje vrši na pokretni poljoprivredni usjev.
when the information about pixel value compensation indicates the second type regarding edge value levels, determining an edge value level of the current pixel (30) by comparing the pixel value of the current pixel (30) to pixel values of neighboring pixels (31, 32, 33, 34, 35, 36 and 37), in the deblocking-filtered image; and 
generiranje vrijednosti piksela trenutnog bloka izvršavanjem dekodiranja na trenutnom bloku i generiranjem vrijednosti obnovljenih piksela trenutnog bloka provođenjem deblokiranja-filtriranja na generiranim vrijednostima piksela trenutnog bloka;
The method according to claim 1, wherein following addition of AMP to the suspension, the suspension is introduced in a container or unit up to a level determined by measurement of the suspension conductivity. 
Uporaba prema zahtjevu 16, naznačena time da se nakon dodavanja navedenog AMP u navedenu suspenziju, suspenzija uvodi u spremnik ili jedinicu do razine određene pomoću mjerenja vodljivosti suspenzije.
The reconstituted formulation of claim 7, wherein the aqueous solution is water or normal saline. 
Rekonstitutirana formulacija u skladu s patentnim zahtjevom 9, naznačena time što je vodena otopina voda ili normalna fiziološka otopina.
A human engineered DKK-1 antibody according to claim 1, wherein the human engineered DKK-1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 18 and a light chain comprising the amino acid sequence of SEQ ID NO: 20. 
Konstruirano protutijelo protiv DKK-1 u skladu s patentnim zahtjevom 1, naznačen time što konstruirano protutijelo protiv DKK-1 sadrži teški lanac, koji ima aminokiselinski slijed SEQ ID NO: 18 i laki lanac, koji ima aminokiselinski slijed SEQ ID NO: 20.
The method of claim 11, wherein said filler material is constituted by concrete. The method of claim 1, wherein said filler material is constituted by inert material in the solid state in granules. 
Postupak prema jednom ili više zahtjeva 1 do 8, naznačen time, da je spomenuti materijal punila (3) sastavljen od inertnog materijala u krutom stanju i oblikovan u granulama.
to 45% of diammonium oxalate, diammonium hydrogen phosphate or ammonium dihydrogen phosphate, 
D) 4 do 45% diamonijevog hidrogen fosfata ili amonijevog dihidrogen fosfata,
A crystalline form (Form A) of N-(3-cyano-4-methyl-1 H- indol-7-yl)-3-cyanobenzenesulfonamide hydrate having a peak at a chemical shift of approximately 134.7 ppm in a 13C solid state NMR spectrum. 
Kristalni oblik (Oblik A) u skladu s patentnim zahtjevom 17 ili 18, naznačen time, da je njegov maksimum u kemijskom pomaku otprilike 134.7 ppm u 13C NMR spektru u krutom stanju.
Of which: Saturated 
Od čega: zasićene
A pharmaceutical formulation comprising the compound of claim 2 and a pharmaceutically acceptable excipient, carrier, or diluent. 
Farmaceutska formulacija, naznačena time, da sadrži spoj iz patentnog zahtjeva 2 i farmaceutski prihvatljiv ekscipijens, nosač ili razrjeđivač.
a VH which comprises in sequence hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence SEQ ID NO:1, said CDR2 having the amino acid sequence SEQ ID NO:2, and said CDR3 having the amino acid sequence SEQ ID NO:3; wherein said hypervariable regions are according to the Kabat definition; or a VH which comprises in sequence hypervariable regions CDR1-x, CDR2-x and CDR3-x, said CDR1-x having the amino acid sequence SEQ ID NO:11, said CDR2-x having the amino acid sequence SEQ ID NO:12, and said CDR3-x having the amino acid sequence SEQ ID NO:13, wherein said hypervariable regions are according to the Chothia definition; and 
VH koji obuhvaća u nizu hipervarijabilna područja CDR1, CDR2 i CDR3, gdje navedeno područje CDR1 ima aminokiselinsku sekvencu SEQ ID NO:1, navedeno područje CDR2 ima aminokiselinsku sekvencu SEQ ID NO:2, i navedeno područje CDR3 ima aminokiselinsku sekvencu SEQ ID NO:3, dok su hipervarijabilna područja određena prema Kabat-definiciji; ili VH koji obuhvaća u nizu hipervarijabilna područja CDR1-x, CDR2-x i CDR3-x, gdje navedeno područje CDR1-x ima aminokiselinsku sekvencu SEQ ID NO:11, navedeno područje CDR2-x ima aminokiselinsku sekvencu SEQ ID NO:12, i navedeno područje CDR3-x ima aminokiselinsku sekvencu SEQ ID NO:13, dok su hipervarijabilna područja određena prema Chothia-definiciji; i
Steel production facility (1) according to claim 1 or 2, characterized in that the electric arc furnace (10) comprises a furnace-shell (13) dimensioned in such a way, that inside there is enough room for 90% or for 80% or for 70% of the maximum amount of shredded scrap-iron pieces in unmolten form that is molten in the course of one cycle of a melting process. 
Postrojenje za proizvodnju čelika (1) prema zahtjevu 1 ili 2, naznačeno time, da elektrolučna peć (10) obuhvaća kućište peći (13) koje je dimenzionirano na takav način, da unutra postoji dovoljno prostora za 90% 1li za 80% 1li za 70% od maksimalne količine izdrobljenih komada lom-željeza u nestaljenom obliku, koji se tale tijekom jednog ciklusa postupka taljenja.
The substrate 38 of the aerosol generator is a granular, thermally stable carbon. A mass of tobacco 28 is located immediately behind the substrate. 
Supstrat 38 generatora aerosola je granuliran, termički stabilan ugljik, čep 28 duhana nalazi se neposredno iza supstrata 38.
wherein the compound of formula (I) is in absolute configuration (S); Ar1 represents 
pri čemu se spoj formule (I) nalazi u apsolutnoj konfiguraciji (S); Ar1predstavlja,, ili;
Anti-Alzheimer's disease active agent for use according to any one of claims 4-9, wherein said genetic variant is a poly-T deletion/insertion polymorphism having a poly-T length of between 20 and 50 base pairs at rs10524523. 
Liječenje s učinkovitom količinom djelotvornog sredstva protiv Alzheimerove bolesti, za uporabu prema bilo kojem zahtjevu od 4 do 8, naznačeno time, da genetička varijanta od TOMM40 gena je rs10524523.
The combined extract was dried (sodium sulfate), filtered to remove solids, and concentrated to give intermediate 28 (4.30 g, 61%) as a light brown solid. 
Kombinirani ekstrakt je sušen (natrij sulfat), filtriran da bi se uklonile čvrste supstance i koncentriran da bi se dobio Intermedijer 28 (4.30 g, 61%) kao svijetlo smeđe čvrsta supstanca.
A method of generating a rearranged human immunoglobulin heavy chain variable region sequence that encodes a human immunoglobulin heavy chain variable domain, the method comprising 
Metoda za proizvodnju humanog antitijela koje sadrži imunoglobulinski teški lanac dobiven iz jednog humanog segmenta gena VH, pri čemu se metoda sastoji od
Freezing point of deionised water, deionised water with sugar replacement composition and deionised water with sugar. 
Ledišta deionizirane vode, deionizirane vode sa sastavinom koja zamjenjuje šećer i deionizirane vode sa šećerom
TLR-3 agonists also include expressed dsRNA (e.g., dsRNA encoded by a nucleic acid comprising a sequence set forth in SEQ ID NOS: 3, 7, 8, 9, 10, 11, or 12). 
Pripravak za primjenu prema zahtjevu 7, naznačen time, što agonist TLR-3 predstavlja nukleinsku kiselinu koja se sastoji od sekvencije odabrane iz grupe koja se sastoji od SEQ ID br.: 3, 4, 5, 8,9, 10, 11112.
in linear form. 
2 je u linearnom obliku.
said thermochromic ink is coloured below about 38° C. and becomes colourless when said temperature is reached or exceeded; and 
(b) navedena termokromna tinta je obojana ispod temperature od oko 38*C i postaje bezbojna kada se dosegne navedena temperatura ili kada se ona prijeđe;
reacting the epoxide mixture 1 (RS, SR, RR and SS) of formula with an amine R-NH2, wherein: 
a. reagiranja smjese od četiri izomera SR, RS, RR i SS epoksida formule (1)
A combination according to claim 4 wherein the anti-inflammatory agent is a corticosteroid or an NSAID. 
Kombinacija u skladu s patentnim zahtjevom 4, naznačen time što je protuupalno sredstvo kortikosteroid ili NSAID.
The antibody of claim 7, wherein said antibody comprises the heavy chain variable region of SEQ ID NO:38. The antibody of claim 1 or 7, wherein said variant comprises a M34I substitution. The antibody of claim 9, wherein said antibody comprises the heavy chain variable region of SEQ ID NO:40 or SEQ ID NO:42. 
Humanizirano protutijelo anti-CD20 tipa II, naznačeno time, da obuhvaća sljedeće: varijabilno područje jakog lanca odabrano iz skupine koju čine SEQ ID NO:32 i SEQ ID NO:40, i varijabilno područje KV1 slabog lanca od SEQ ID NO:76.
A process according to claim 1, wherein the thieno-pyridine compound of Formula I is selected from the group consisting of: 
Spoj prema zahtjevu 1 naznačen time da je odabran iz skupine koju čine:
Said upper layer 19 is constituted by an external peripheral or perimetric skirt 20 and is constituted centrally by a breathable element 21. 
Navedeni gornji sloj 19 je sastavljen od vanjske periferne ili obodne oplate 20, a u središnjem dijelu se nalazi prozračni element 21.
Another preferred group of the compounds of Group A consists of those wherein R1 is hydrogen or methyl, R2 is methyl, W is hydrogen and Z is selected from the group consisting of 3,4-dichlorophenyl, 3-trifluoromethyl-phenyl, 4-chlorophenyl, 4-bromophenyl and 3-trifluoromethyl-4-chloro-phenyl. 
Druga poželjna skupina spojeva iz skupine A sastoji se od onih u kojima je R; vodik ili metil, R, je metil, W je vodik i Z se bira iz skupine koja sadrži 3,4-diklorofenil, 3-trifluorometilfenil, 4-klorofenil, 4-bromofenil i 3-trifluorometil-4-klorofenil.
A method according to claim 1 or claim 2 wherein said determining is through the use of a Melanophore assay, through the use of a reporter assay, or through the measurement of GTPYS binding to a membrane comprising said GPCR. 
Postupak u skladu sa zahtjevom 1 ili zahtjevom 2, naznačen time, da se navedeno određivanje provodi preko uporabe Melanophore ispitivanja, preko uporabe ispitivanja izvješća ili preko mjerenja vezivanja GTPyS na membranu koja sadrži navedeni GPCR.
The composition of claim 13, wherein the total concentration of the common carrier protein in the composition is less than 100 ug/ml. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time da je ukupna koncentracija zajedničkog nosača u sastavu manja od 100 ug/ml.
More preferably, it has at least 50%, at least 60%, at least 70%, at least 80% or, most preferably, at least 90% identity or homology thereto. 
Još poželjnije, mutein posjeduje najmanje 50%, najmanje 60%, najmanje 70%, najmanje 80% ili najpoželjnije najmanje 90% potrebne identičnosti ili homologije.
This experiment clearly demonstrates that oral administration of 42-O-(D-fructosylcarbonyl)rapamycin resulted in little or no overt sign of gastrointestinal toxicity in a hypersensitive dog model as compared to rapamycin which led to signs of severe toxicity. 
Ovaj pokus jasno pokazuje da oralna primjena 42-O-(D-fruktozilkarboniljrapamicina dovodi do malo ili nimalo vidljivih znakova gastrointestinalne toksičnosti u hipersenzitivnom modelu psa u usporedbi s rapamicinom, koji dovodi do znakova teške toksičnosti.
The resulting flocs were dried using a continuously heated alumina mortar on a hot plate to give the final dried powder. 
Nastale okrupnjene čestice su sušene korištenjem kontinuiranog zagrijavanja u aluminijskom tarioniku na rešou i dobiven je konačni suhi prašak.
The process of claim 1, wherein the water soluble and/or water swellable material particles are added stepwise to the core particles and substantially water insoluble polymer particles during the mixing step. 
Postupak sukladno zahtjevu 1, naznačeno time, da se u vodi topive materijalne čestice, koje bubre u vodi postepeno dodaju česticama jezgre i u vodi potpuno netopivim polimernim česticama tijekom koraka miješanja.
The acyl chloride starting compound (III) in Scheme 3 is typically obtained by reaction of the acid (II) with a suitable chlorinating agent, e.g. 
Početni se spoj acil klorid (TIT) u shemi 3 u pravilu dobije reakcijom kiseline (II) s pogodnim agensom za kloriranje, pr.
or in the manufacture of a diagnostic or prognostic reagent for use in the diagnosis or prognosis of a tau proteinopathy of patient wherein the compound incorporates, is conjugated to, is chelated with, or is otherwise associated with, one or more detectable labels. A method of labelling or detecting tau protein or aggregated tau protein in vitro, said method comprising the steps of: 
kompleksa disinhibicija-demencija-parkinsonizam-amiotrofija (DDPAC), palido-pronto-nigralne degeneracije (PPND), Guam-ALS-sindroma, palido-nigro-lujzijanske degeneracije (PNLD), ili kortiko-bazalne degeneracije (CBD) kod pacijenta; ili je za proizvodnju dijagnostičkog ili prognostičkog reagensa za primjenu u dijagnozi ili prognozi tau proteinopatije kod pacijenta, pri čemu spoj utjelovljuje, konjugiran je na, kelatiran je, ili je udružen na neki drugi način s jednom/jednu ili više oznaka koje se mogu detektirati.
Wind system (1) according to claim 2, characterised in that said spring is compressed due to said tension of said rope (4). 
Vjetreni sustav (1) prema zahtjevu 6, naznačen time da je spomenuta rastegnuta fleksibilna konstrukcija (12) opremljena jednom okomitom rešetkastom konstrukcijom (13).
Method according to claim 15 or 16, characterised in that the immunoglobulin contains any of the structural loop regions of a variable domain comprising a modification in once out the amino acid positions within the amino acid sequence selected from the group consisting of amino acids 8 to 20, amino acids 44 to 50, amino acids 67 to 76 and amino acids 89 to 101, wherein the numbering is according to IMGT. 
Postupak u skladu sa zahtjevom 15 ilil6, naznačen time, da imunoglobulin obuhvaća neko od podučja strukturne petlje varijabilne domene koja sadrže modifikaciju u jednom vanjskom aminokiselinskom položaju unutar aminokiselinske sekvence izabrane iz skupine koju čine aminokiseline 8 do 20, aminokiseline 44 do 50, aminokiseline 67 do 76 i aminokiseline 89 do 101, pri čemu je numeriranje prema IMGT.
a total amount of protein of at least 4% (w/w) 
– vodu, – sladilo, – ukupnu količinu proteina od najmanje 4 % (tež./tež.)
converting compound 6 to a compound of formula 7 
e) Pretvorbu spoja 6 u spoj formule 7;
A conjugate according to claim 1 or 2, for delivery drugs across a blood-tissue barrier. 
Konjugat u skladu s patentnim zahtjevom 1 ili 2, za dopremanje lijekova kroz krvno-tkivnu barijeru.
The aqueous pharmaceutical suspension according to claim 3, further comprising, by weight/volume (g/100 mL), 2.5% to 5.0% of propylene glycol. 
Vodena farmaceutska-suspenzija u skladu s patentnim zahtjevom 7, naznačena time što izborno dodatno sadrži, težinski/volumno (g/100 ml), otprilike 2,5 % do otprilike 5,0 % propilen-glikola.
Method and system for distributing data packets on communication channel and stationary modular transceiver devices for performing the method and system 
METODA I SUSTAV ZA RASPODJELU PAKETA PODATAKA NA KOMUNIKACIJSKI KANAL I STACIONARNI MODULARNI PRIMOPREDAJNICI ZA IZVOĐENJE METODE I SUSTAVA
n = number of events 
(21) Broj predmeta:
Inhibitors were solubilized in DMSO (final solvent concentration in the reaction medium, 1%). 
Inhibitori su otopljeni u DMSO-u (konačna koncentracija otapala u reakcijskom mediju: 1 %).
The method of any preceding claim, wherein the one of the possible media items is selected for output in the slot on the basis of priority data associated with at least some of the possible media items scheduled for output in that slot. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se jednu od mogućih medijskih točaka bira za izlaženje u rupi na osnovi podataka o prioritetu povezanih s u najmanju ruku nekim od mogućih medijskih točaka na rasporedu za izlaženje u toj rupi.
optionally to transform GalNAc acid salt of formula V into the GalNAc acid derivative of formula I. 
€) po izboru transformiranje GalNAC kiselinske soli formule V u derivat GalNAc kiseline formule I.
Packaging unit according to one or more of the foregoing claims, wherein the front surface of the bottom part comprises a protrusion (56), and the cover part comprises a front surface provided with a corresponding opening (58) together defining a lock (44, 64), and wherein the label comprises a surface provided with an embossing (60) at the location of the opening in the cover front surface to enhance the locking function of the lock. 
Jedinica za pakiranje prema jednom ili više od prethodnih zahtjeva, naznačena time da prednja površina donjeg dijela ima izbočinu (56), i pokrovni dio ima prednju površinu koja ima odgovarajući otvor (58) zajedno definiraju bravu (44, 64), te pri čemu oznaka sadrži površinu s utiskivanjem (60) na mjestu otvora na prednjoj površini poklopca kako bi se poboljšala funkcija zaključavanja brave.
Figure 10 is a diagram showing the connection of the receiver, used in the present invention, to a device for generating an external acoustic signal; and 
Slika 10 je dijagram koji prikazuje spoj prijemnika, koji se koristi u opisanom izumu, i uređaja za generiranje vanjskog akustičkog signala; te
A composition for use as claimed in claim 1, wherein said muscle recovery is muscle recovery following exercise. 
Pripravak za upotrebu prema zahtjevu 1, naznačen time da je navedeni oporavak mišića oporavak mišića poslije vježbanja.
A compound of formula (I) according to claim 1 wherein R3 is C4-8alkyl substituted with hydroxyl, and wherein R2 and R1 are as specified above. 
Spoj formulom (1) prema zahtjevu 1 naznačen time što R, je arilalkil ili heteroarilalkil, supstituiran s C;salkilom, hidroksilom, alkoksi, nitrilom, heterociklom ili esterom i pri čemu R, i Rs su kao što je gore navedeno.
an Evolved Universal Terrestrial Radio Access Network technology, 
Evoluirana tehnologija univerzalne zemaljske pristupne radio mreže (engl. Evolved Universal Terrestrial Radio Access Network),
A tablet as described in any one of claims 1-21 for use in the prophylactic or therapeutic treatment of an HIV infection, wherein rilpivirine AUC achieved following administration to the human when fed is no more than about 25% greater than rilpivirine AUC achieved when administered to the human when fasted or wherein rilpivirine Cmax achieved following administration to the human when fed is no more than about 25% greater than rilpivirine Cmax achieved when administered to the human when fasted. 
Tableta kao što je opisano u bilo kojem od zahtjeva 1-21 za primjenu u profilaktičkom ili terapeutskom tretmanu HIV infekcije, gdje rilpivirin AUC (area under the curve-površina ispod krivulje) koji je postignut primjenom kod čovjeka uz ishranu nije više od oko 25% veći od rilpivirin AUC koji je postignut primjenom kod čovjeka na dijeti ili gdje rilpivirin Cpyx koji je postignut primjenom kod čovjeka uz ishranu nije više od oko 25% veći od rilpivirin Cinax koji je postignut primjenom kod čovjeka na dijeti.
An abuse-proofed, thermoformed dosage form having a breaking strength of at least 500 N, said dosage form being in the form of a tablet obtained by a process comprising: 
Oblik davanja lijeka prema patentnom zahtjevu 1, naznačen time, da je u obliku tablete.
5% to 40% by weight of progesterone; 
od 5 % do 40 % progesterona u odnosu na masu
The third layer 13 of aluminum powder is provided by no more than 0.05 grams of aluminum powder per square meter, an amount that fully achieves the aim of acting as a barrier against light and infrared radiation. 
Treći sloj 13 od aluminijskog praha izrađen je od najviše 0,05 grama aluminijevog praha po kvadratnom metru, količine koja potpuno dostiže cilj djelovanja u smislu pregrade prema svjetlu i infracrvenom zračenju.
Coating composition according to claim 1 or 2, characterised in that said SMGCC has a volume median diameter d 50 of between 0.08 and 0.3 µm, preferably of between 0.1 and 0.2 µm, e.g. 
Sastav za oblaganje u skladu s patentnim zahtjevom 1, karakteriziran na način da navedeni sastav za oblaganje ima PVC od 15 do 25%.
Use according to claim 9, characterized in that the respiratory disease is asthma or COPD. 
Uporaba sukladno patentnom zahtjevu 9, naznačena time, da je bolest dišnih putova astma ili kronična opstruktivna plućna bolest (COPD).
A is phenyl which may be substituted by X, naphthyl which may be substituted by X, heterocyclic ring which may be substituted by X, or fused heterocyclic ring which may be substituted by X; B is a 5-membered heterocyclic ring, which is substituted by Y; X is halogen, alkyl, haloalkyl, alkoxyalkyl, dialkylaminoalkyl, alkynyl, trialkylsilyfalkynyl, hydroxy, alkoxy, haloalkoxy, alkoxyalkoxy, cycloalkyl, nitro, phenyl, phenylalkynyl, pyridyloxy which may be substituted by haloalkyl, alkylcarbonyloxy, alkylsulfonyloxy, or heterocyclic ring (the heterocyclic ring may be substituted by halogen, alkyl, or alkylcarbonyl); 
(1) naznačen time, da A jefenil koji se može supstituirati s X, naftil koji se može supstituirati s X, heterociklički prsten koji se može supstituirati s X, ili stopljeni heterociklički prsten koji se može supstituirati s X; je 5-eročlani heterociklički prsten, koji je supstituiran s Y; je halogen, alkil, haloalkil, alkoksialkil, dialkilaminoalkil, alkinil, trialkilsililalkinil, hidroksi, alkoksi, haloalkoksi, alkoksialkoksi, cikloalkil, nitro, fenil, fenilalkinil, piridiloksi, koji se može supstituirati s haloalkilom, alkilkarboniloksi, alkilsulfoniloksi ili heterociklički prsten (heterociklički prsten može se supstituirati s halogenom, alkilnom ili alkilkarbonilom);
A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein 
' naznačen time što je međuprodukt u dobivanju spoja formule (I) u skladu s patentnim zahtjevom 8.
5-Nitro-biphenyl-2-carboxylic acid (25 mmol) was suspended in 1,2-dichloroethane (100 mL) and two drops of DMF was added followed by drop wise addition of oxalylchloride (2M solution in dichloromethane) (40 mmol). 
5-nitro-bifenil-2-karboksilna kiselina (25 mmol) se suspendira u 1,2-dikloroetanu (100 ml) i dodaju se dvije kapi DMF, praćeno polaganim dodavanjem oksalilklorida (2M otopina u diklorometanu) (40 mmol).